30 results about "Pneumococcal vaccine" patented technology

The present invention relates to new pneumococcal vaccines. The invention also relates to vaccination of subjects, in particular immunocompromised subjects, against pneumococcal infections using said novel pneumococcal vaccines.

The invention relates to bacterial choline binding proteins (CBPs) which bind choline. Such proteins are particularly desirable for vaccines against appropriate strains of Gram positive bacteria, particularly streptococcus, and more particularly pneumococcus. Also provided are DNA sequences encoding the bacterial choline binding proteins or fragment thereof, antibodies to the bacterial choline binding proteins, pharmaceutical compositions comprising the bacterial choline binding proteins, antibodies to the bacterial choline binding proteins suitable for use in passive immunization, and small molecule inhibitors of choline binding protein mediated adhesion. Methods for diagnosing the presence of the bacterial choline binding protein, or of the bacteria, are also provided. In a specific embodiment, a streptococcal choline binding protein is an enolase, which demonstrates strong affinity for fibronectin.

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention thereforerelates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

Plasmid DNA encoding at least one pneumococcal antigen or epitope of interest and methods for making and using such a plasmid are disclosed and claimed. The epitope of interest can be PspA or a fragment thereof. Compositions containing the plasmid DNA are useful for administration to a host susceptible to pneumococcal infection for an in vivo response, such as a protective response, or for generating useful antibodies. The inventive plasmid can also be transfected into cells for generating antigens or epitopes of interest in vitro. And the inventive plasmid can be prepared by isolating DNA (coding for: promoter, leader sequence, epitope of interest and terminator), and performing a three-way ligation. More particularly, administration of DNA encoding pneumococcal antigens or epitopes of interest and compositions therefor for eliciting and immunological response against S. pneumoniae, such as a protective response preventive of pneumococcal infection, are disclosed and claimed. Thus, pneumococcal vaccines or immunological compositions, and methods of making and using them, are disclosed and claimed.

Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6C, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit {2) glucose 1 (1→3) glucose 2 (1→3) rhamnose (1→3) ribitol (5→phosphate}. This new serotype may be included in pneumococcal vaccines.

This invention relates to a live mutated strain of S. pneumoniae which is incapable of expressing polysaccharide capsule, while still capable of colonizing the nasopharynx of the subject.

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

A pneumococcal vaccine comprising a fusion protein at least comprising a full-length family 1 pneumococcal surface protein A (PspA) or a fragment thereof, and a full-length family 2 PspA or a fragment thereof, in particular any one of the following fusion proteins (1) to (3):(1) a fusion protein at least comprising a family 1, clade 2 PspA and a family 2, clade 3 PspA,(2) a fusion protein at least comprising a family 1, clade 2 PspA and a family 2, clade 4 PspA, and(3) a fusion protein at least comprising a family 1, clade 2 PspA and a family 2, clade 5 PspA,is useful as a pneumococcal vaccine comprising a single protein antigen that has broadly cross-reactive immunogenicity and can induce immune response against a wide range of pneumococcal clinical isolates.

The invention relates to bacterial choline binding proteins (CBPs) which bind choline. Such proteins are particularly desirable for vaccines against appropriate strains of Gram positive bacteria, particularly streptococcus, and more particularly pneumococcus. Also provided are DNA sequences encoding the bacterial choline binding proteins or fragment thereof, antibodies to the bacterial choline binding proteins, pharmaceutical compositions comprising the bacterial choline binding proteins, antibodies to the bacterial choline binding proteins suitable for use in passive immunization, and small molecule inhibitors of choline binding protein mediated adhesion. Methods for diagnosing the presence of the bacterial choline binding protein, or of the bacteria, are also provided. In a specific embodiment, a streptococcal choline binding protein is an enolase, which demonstrates strong affinity for fibronectin.

Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6C, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit {→2) glucose 1 (1→3) glucose 2 (1→3) rhamnose (1→3) ribitol (5→phosphate}. This new serotype may be included in pneumococcal vaccines.

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 10A and 39, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 10A and 39, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

The invention relates to a fusion gene. The fusion gene is characterized in that a dominant antigen area P1a-P30a of mycoplasma pneumoniae P1 and P30 is subject to fusion expression; the PLY-P1a-P30ais subject to fusion expression by a gene of pneumolysin PLY and one part of genes of mycoplasma pneumoniae P1 and P30; the immunogenicity of the protein PLY-P1a-P30a is obviously better than the immunogenicity of P1a-P30a; the immunogenicity of the mycoplasma pneumoniae subunit P1a-P30a is enhanced; the immunity function of streptococcus pneumoniae is realized, and the toxicity of mouse is not observed in clinical application; the fusion gene PLY-P1a-P30a is a gene resource with lower cost, the expression quantity of subunit vaccine of the fusion gene PLY-P1a-P30a is high, and the purification and preparation are easy; the stability and immune activity can be maintained for two years or more at the temperature of -80 DEG C; compared with the conventional deactivating vaccine and weak-toxic vaccine, the preparation cost is obviously reduced, and the foundation is laid for the study of mycoplasma pneumoniae and streptococcus pneumoniae vaccines.

Immunogenic composition are provided comprising PnCo and / or GlpO polypeptides identified as being preferentially expressed during the virulent phase of an infection related to streptococcal bacteria. The compositions can be used for eliciting immune response against streptococcal infections, such as against infections caused by S. pneumoniae.

The invention relates to a method for preparing pneumococcal capsular polysaccharide and a pneumococcal vaccine. A method of making a pneumococcal capsular polysaccharide comprises providing a pneumococcal lysate of a selected serotype; removing proteins and nucleic acids from the lysate, the removal of proteins and the removal of nucleic acids being performed out of order in separate steps; the method for removing the protein comprises the following steps: I) mixing a sample to be treated with sodium deoxycholate to enable the pH value of the mixed system to be 3-6, centrifuging to obtain supernate, and adjusting the pH value of the supernate to be 6-8 to obtain first supernate; iI) removing sodium deoxycholate in the first supernate; the method for removing the nucleic acid comprises the following steps: A) mixing a sample to be treated with divalent salt to enable the pH value of the mixed system to be 1-4, centrifuging to obtain supernate, and adjusting the pH value of the supernate to be 6-8 to obtain second supernate; and B) removing the divalent salt added in the step A) in the second supernatant. The method is simple and ingenious, and an excellent pneumococcus capsular polysaccharide purification effect is achieved.

The invention discloses a streptococcus pneumoniae vaccine and a preparation method thereof. The streptococcus pneumoniae vaccine is prepared by mixing S3CS recombinant antigens or mutant protein antigens with additives. The vaccine can be applied to immunity; the protection of organisms on streptococcus pneumonia can be improved; a specific antibody can be generated. A preparation method of the vaccine is simple; the requirements of large-scale industrial production can be met.

The present invention provides D39-derived mutant PspA that does not undergo deamination and maintains molecular stability even at near-neutral pH. Specifically, the present invention is the following protein (a) or (b). (a) A protein that includes the amino acid sequence represented by sequence no. 2 and that has pneumococcus vaccine antigenic activity, and a protein substantially the same as said protein; and (b) a protein that includes a portion of the amino acid sequence represented by sequence no. 2, said portion including aspartic acid at position 254, and that has pneumococcus vaccine antigenic activity, and a protein substantially the same as said protein.

Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6D, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit→2) glucose 1 (1→3) glucose 2 (1→3) rhamnose (1→4) ribitol (5→phosphate. This new serotype may be included in pneumococcal vaccines.